Back to search results

Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

This study is for men with prostate cancer to understand and improve their heart health. It tests different ways to lower the risk of heart problems like heart attacks and strokes. You might receive advice on healthy eating (Nutrition), exercise, and quitting smoking (Smoking cessation). You could also be prescribed medications like statins (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) to help with cholesterol, or ACE inhibitors to help with blood pressure. The study is looking for men aged 45 and older who have a recent prostate cancer diagnosis or are starting Androgen Deprivation Therapy (a common prostate cancer treatment). We will measure how well these approaches help control cholesterol and blood pressure, and prevent serious heart events over 3-5 years.

Study design
This study plans to enroll 5000 men. It includes two parts: one that observes men with prostate cancer (RADICAL PC1) and another that tests specific interventions (RADICAL PC2).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3-5 years to track heart health outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03127631

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Active, Not Recruiting
NAAges 45+InterventionalTreatment
McMaster University
~5,000 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:NutritionExerciseSmoking cessationStatin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)ACE inhibitor

At a glance

Recruiting sites
0 of 61 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
Measured over 3-5 years
+1 more outcome measured

Conditions

Prostate Cancer
Cardiovascular Disease

Explore related trials

Prostate Carcinoma

Where it's being run

61 sites across 26 states
São Paulo13
Ontario10
Quebec6
Rio Grande do Sul4
Paraná3
Israel3
South Australia2
Minas Gerais2

Study leadership

  • Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC · STUDY_DIRECTOR · McMaster University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit

What this trial measures

  • Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).3-5 years

    Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).

  • Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.3-5 years

    Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.